Literature DB >> 9881707

Inhibition of tumor growth and invasion by a four-kringle antagonist (HGF/NK4) for hepatocyte growth factor.

K Date1, K Matsumoto, K Kuba, H Shimura, M Tanaka, T Nakamura.   

Abstract

Invasion of various carcinoma cells follows their interaction with stromal cells. Hepatocyte growth factor (HGF), four-kringle-containing growth factor, is a mesenchymal or stromal-derived mediator which affects the growth and the invasiveness of carcinoma cells. We now have evidence that a four-kringle-containing antagonist for HGF, HGF/NK4 inhibits invasion of tumors in vivo, as well as in vitro. HGF/NK4 competitively inhibited the binding of HGF to Met/ HGF receptors on GB-d1 human gallbladder carcinoma cells. HGF induced invasion of the cells through Matrigel basement membrane components and into collagen gels, but HGF-induced invasion was inhibited by HGF/NK4. Invasion of GB-d1 cells was induced by co-cultivation with stromal fibroblasts, which mimics tumor-stromal interaction, but it was almost completely suppressed by HGF/NK4. Likewise, invasive growth induced by HGF in collagen gels in GB-dl cells, HuCC-T1 human cholangiocarcinoma cells, and ME-180 human uterus cervical carcinoma cells was also strongly inhibited by HGF/NK4. When GB-d1 cells were implanted subcutaneously into nude mouse, tumor cells invaded muscular tissue, but the infusion of HGF/NK4 inhibited this invasion. Furthermore, HGF/NK4 increased apoptotic cell death of GB-d1 cells and inhibited tumor growth in vivo. These results indicate that HGF/ NK4 may inhibit growth and invasion of carcinoma cells, as mediated by HGF during tumor-stromal interactions. We propose that there is a unique therapeutic potential for HGF/NK4 to prevent tumor invasion and perhaps even metastasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9881707     DOI: 10.1038/sj.onc.1202231

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

2.  Induction of c-met proto-oncogene expression at the metastatic site.

Authors:  J Imai; M Watanabe; M Sasaki; R Yamaguchi; S Tateyama; S Sugano
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

Review 3.  Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment.

Authors:  Boris Blechacz; Gregory J Gores
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

4.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

5.  Cholangiocarcinoma: expanding the spectrum of risk factors.

Authors:  Diaa H Elfaki; Andrea A Gossard; Keith D Lindor
Journal:  J Gastrointest Cancer       Date:  2009-01-14

6.  Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice.

Authors:  Xiao-Ping Chen; Xin-Ping Ren; Jian-Yun Lan; You-Guo Chen; Zong-Ji Shen
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

7.  Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres.

Authors:  Toshihiro Kushibiki; Kunio Matsumoto; Toshikazu Nakamura; Yasuhiko Tabata
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

Review 8.  MET as a target for treatment of chest tumors.

Authors:  Nicole A Cipriani; Oyewale O Abidoye; Everett Vokes; Ravi Salgia
Journal:  Lung Cancer       Date:  2008-07-30       Impact factor: 5.705

9.  Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.

Authors:  Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler
Journal:  BMC Cancer       Date:  2010-06-18       Impact factor: 4.430

10.  NK4 gene therapy inhibits HGF/Met-induced growth of human cholangiocarcinoma cells.

Authors:  Xianxiu Ge; Youli Wang; Yun Wang; Quanpeng Li; Hong Yu; Lin Miao
Journal:  Dig Dis Sci       Date:  2013-01-12       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.